Company
Headquarters: South San Francisco, CA, United States
Employees: 15
CEO: Dr. Marshall Fordyce M.D.
$3.07 Billion
USD as of Jan. 1, 2025
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $113.24 B |
CSL Limited | $95.75 B |
Regeneron Pharmaceuticals, Inc. | $76.33 B |
Marinomed Biotech AG | $56.13 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Last Financial Reports Date | Sept. 30, 2024 |
Revenue TTM | $0 |
EBITDA | $0 |
Gross Profit TTM | $0 |
Profit Margin | 0.00% |
Operating Margin | 0.00% |
Quarterly Revenue Growth | % |
Vera Therapeutics, Inc. has the following listings and related stock indices.
Stock: NASDAQ: VERA wb_incandescent